Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIROMATRIX MEDICAL INC.

(MIRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIROMATRIX MEDICAL INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

10/14/2021 | 07:49am EST

Item 7.01Regulation FD Disclosure.

On October 14, 2021, Miromatrix Medical Inc. (the "Company") contributed an article to a blog on the website Nature.com. A copy of the Company's article is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this item 7.01 and Exhibit 99.1 is being furnished, and shall not be deemed to be "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under Section 18. Furthermore, the information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be incorporated by reference into the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01Financial Statements and Exhibits.

(d)    Exhibits.

99.1     Article, dated October 14, 2021
104    Cover Page Interactive File (the cover page tags are embedded within the
       Inline XBRL document)

© Edgar Online, source Glimpses

All news about MIROMATRIX MEDICAL INC.
11/15MIROMATRIX MEDICAL : Reports Third Quarter 2021 Results - Form 8-K
PU
11/15MIROMATRIX MEDICAL INC. Management's Discussion and Analysis of Financial Condition an..
AQ
11/15Miromatrix Reports Third Quarter 2021 Results
GL
10/28Miromatrix to Report Third Quarter 2021 Financial Results
AQ
10/14SUCCESSFUL TRANSPLANT OF BIOENGINEER : Jeff Ross, Ph.D - Form 8-K
PU
10/14MIROMATRIX MEDICAL INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
10/07MIROMATRIX MEDICAL : Completes First Transplant Using Bioengineered Liver in Large Animal
MT
10/07MIROMATRIX MEDICAL : Preclinical study of clinically relevant liver transplants advances t..
PU
10/07MIROMATRIX MEDICAL INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
10/07MIROMATRIX MEDICAL : Announces the First Successful Transplant of a Bioengineered Whole Or..
AQ
More news
Analyst Recommendations on MIROMATRIX MEDICAL INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -12,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,42x
Yield 2021 -
Capitalization 135 M 135 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 36
Free-Float 90,9%
Chart MIROMATRIX MEDICAL INC.
Duration : Period :
Miromatrix Medical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 6,65 $
Average target price 22,00 $
Spread / Average Target 231%
EPS Revisions
Managers and Directors
Jeff Ross Chief Executive Officer & Director
Brian A. Niebur Chief Financial Officer & Vice President-Finance
Paul R. Buckman Chairman
John L. Erb Independent Director
Peter K. Maag Director
Sector and Competitors
1st jan.Capi. (M$)
MIROMATRIX MEDICAL INC.0.00%135
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298